MK-677 (Ibutamoren) — Non-Peptide
An investigational oral small-molecule ghrelin-receptor agonist—not a peptide and not an FDA-approved drug.
OVERVIEW
MK-677 (ibutamoren) is an oral small-molecule ghrelin-receptor agonist that can increase growth hormone signaling. It is commonly grouped with peptides in wellness discussions, but it is not a peptide.
Proposed Mechanisms
• Ghrelin-receptor agonism • Growth hormone release • Downstream IGF-1 signaling
Potential Applications
• Investigational growth-hormone signaling research • Recovery, sleep, and body-composition research
Pharmacokinetics
The source draft cited an approximately 24-hour half-life; product-specific human data and purity are not established for marketed research products.
Dosing
No FDA-approved human dosing. The source draft listed 10–25 mg nightly; this is an investigational protocol reference only.
Monitoring
• IGF-1 • Fasting glucose • A1c • Weight and fluid retention • Adverse effects
Side Effects
Not fully summarized in the source draft. Glucose, edema/fluid-retention, appetite, and other growth-hormone-pathway effects require clinical consideration.
Contraindications
No FDA-approved labeling or established contraindication profile; clinician review is required.
FDA/Investigational Status
Not FDA-approved. FDA enforcement materials have identified marketed MK-677 products as unapproved new drugs.
Disclaimer/Notes
Label clearly as non-peptide. Educational resource only; do not present as a routine therapy or approved growth-hormone alternative.
Clinical Review Status
Clinical + legal review required before publishing